Day: March 1, 2022

PRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2021 and updated guidance for 2022. Fourth Quarter Highlights:Revenue was $75.3 million, compared to $64.6 million in the fourth quarter of 2020, representing growth of 17% over the fourth quarter of 2020. Excluding Pinnacle 21, revenue was $69.3 million, representing growth of 7% over the fourth quarter of 2020. Net loss was $9.7 million, compared to net loss of $54.5 million in the fourth quarter of 2020, representing a decrease of $44.7 million over the fourth quarter of 2020. Adjusted EBITDA was $28.2 million, compared to $22.2 million in the fourth quarter of 2020, representing growth of 27% over the fourth quarter of 2020.Full Year...

– Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC) reported in 2021 – – First-in-human study of CX-904 in advanced solid tumors to be initiated in first half of 2022 – – Initial data for Arms A and B in Phase 2 study of praluzatamab ravtansine in breast cancer expected in second half of 2022 – SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported fourth quarter and full year 2021 financial results, and provided a business update. “2021 was a successful year of sustained execution and delivery on CytomX’s commitment to destroying cancer differently, highlighted by the significant progress advancing...

ALPHARETTA, Ga., March 01, 2022 (GLOBE NEWSWIRE) — GCP Applied Technologies Inc. (NYSE: GCP) (GCP or the Company), a leading global provider of construction products, today announced financial and operating results for the fourth quarter and full year 2021. Fourth Quarter 2021 HighlightsNet sales $244.3 million, an increase of 0.7% Selling, general and administrative expenses of $64.6 million, a decrease of 1.7% Income from continuing operations attributable to GCP shareholders of $1.8 million Adjusted EBIT* of $18.8 million Adjusted EBITDA* of $31.0 million Adjusted EPS of $0.12Full Year 2021 HighlightsNet sales of $970.1 million, an increase of 7.4% Selling, general and administrative expenses of $254.6 million, a decrease of 3.7% Income from continuing operations attributable to GCP shareholders of $21.5 million Adjusted...

Strong Origination Volumes Drive SLRC to its Target Leverage Range; Declares Quarterly Distribution of $0.41 Per Share for Q1, 2022 NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) — SLR Investment Corp. (NASDAQ: SLRC) (the “Company” or “SLRC”) today reported net investment income of $14.9 million, or $0.35 per share, for the fourth quarter of 2021. For the fiscal year ended December 31, 2021, the Company reported net investment income of $60.9 million, or $1.44 per share. At December 31, 2021, net asset value (NAV) was $19.93 per share. The Company’s Board of Directors declared a first quarter 2022 distribution of $0.41 per share, payable on April 1, 2022 to stockholders of record on March 18, 2022. The specific tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year. HIGHLIGHTS:...

KAPALUA RESORT, Hawaii, March 01, 2022 (GLOBE NEWSWIRE) — Maui Land & Pineapple Company, Inc. (NYSE: MLP) today announced financial results for the fourth quarter and year ended December 31, 2021. Results for Year Ended December 31, 2021 Net loss increased to $(3.4) million, or $(0.18) per share, compared to a net loss of $(2.6) million, or $(0.14) per share, for the year ended December 31, 2020. Operating revenues increased to $12.4 million, compared to $7.5 million for the year ended December 31, 2020. Total comprehensive income increased to $2.6 million, or $0.13 per share,, compared to a comprehensive loss of $(3.5) million, or $(0.19) per share, for the year ended December 31, 2020. The Company recorded a pension gain adjustment of $6.0 million, or $0.31 per share, compared to a pension loss adjustment of $(0.9) million,...

Company Reports Record Revenues SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its fourth quarter and full-year ended December 31, 2021. 2021 Full Year and Fourth Quarter HighlightsReported fourth quarter 2021 revenue of $4.3 million, an increase of 15% compared with the fourth quarter of 2020. Reported revenue of $16.3 million for the full year 2021, a 27% increase over 2020 and representing the seventh consecutive year of growth.Increased biologics and drug delivery revenue to $6.8 million for the full year 2021, a 31% increase over 2020.Supported 929 cases in 2021 despite the continued challenges posed by the COVID-19 pandemic.Completed...

IRVINE, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage,” the “Company,” “we” or “our”), a leading provider of outsourced sales and marketing services to consumer goods manufacturers and retailers, today reported financial results for its fiscal fourth quarter and full fiscal year ended December 31, 2021. “We had a solid finish to 2021, converting strong revenue growth to healthy EBITDA gains,” said Advantage Solutions Chief Executive Officer Tanya Domier. “As we emerge from Omicron, our sampling events grew 20% quarter over quarter, while at-home demand stayed healthy, driven by robust pricing and modest unit growth. Our higher margin digital services grew double digits. We continued to invest heavily in recruiting and retention to stand up thousands of new associates, funded in part...

Advanced programs across NGM Bio’s pipeline in retinal diseases, oncology and liver and metabolic diseases during the fourth quarter and beginning of 2022:Obtained Fast Track designation from the U.S. Food and Drug Administration (FDA) for NGM621, an anti-complement C3 antibody product candidate, for the treatment of patients with geographic atrophy (GA) secondary to age-related macular degeneration Completed enrollment in the Phase 2b ALPINE 4 trial of aldafermin, an engineered FGF19 analog product candidate, in patients with compensated NASH cirrhosis (F4 NASH), with topline data expected in the first half of 2023$366.3 million in cash, cash equivalents and marketable securities as of December 31, 2021  SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM),...

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. Recent EventsInitiated a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis in the fourth quarter of 2021. Reported topline data from ENIGMA 2, a Phase 3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with eosinophilic gastritis/eosinophilic duodenitis (“EG”/“EoD”) in the fourth quarter of 2021. Reported topline data from KRYPTOS, a Phase 2/3 randomized, double-blind,...